Cannell Capital LLC Buys 40,235 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Cannell Capital LLC grew its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 1.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,639,545 shares of the company's stock after buying an additional 40,235 shares during the period. MiMedx Group makes up 7.2% of Cannell Capital LLC's portfolio, making the stock its 4th largest position. Cannell Capital LLC owned approximately 2.48% of MiMedx Group worth $35,012,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Invesco Ltd. raised its holdings in MiMedx Group by 2.2% during the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company's stock worth $544,000 after buying an additional 1,226 shares during the period. Trexquant Investment LP increased its position in shares of MiMedx Group by 29.7% during the fourth quarter. Trexquant Investment LP now owns 221,262 shares of the company's stock worth $2,129,000 after acquiring an additional 50,635 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of MiMedx Group by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 389,706 shares of the company's stock worth $3,749,000 after acquiring an additional 72,432 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in MiMedx Group by 484.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock valued at $3,487,000 after acquiring an additional 300,433 shares in the last quarter. Finally, Norges Bank acquired a new position in MiMedx Group in the 4th quarter worth $4,020,000. Institutional investors own 79.15% of the company's stock.

Remove Ads

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This trade represents a 11.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MDXG. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com raised MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 4th.

MiMedx Group Stock Down 0.3 %

MDXG traded down $0.02 during trading hours on Friday, hitting $6.84. 1,143,100 shares of the company's stock were exchanged, compared to its average volume of 697,029. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The stock's 50-day moving average is $7.86 and its two-hundred day moving average is $8.00. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 12.44 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Sell-side analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.